Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Annovis Bio, Inc.NYSE: ANVS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $182.82K fell 63.4% year over year, behind the -62.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 48.7% from the prior quarter. Over 3 fiscal years it compounded at +481.3% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -63.4% toward the trailing-twelve-month pace of -62.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 1.8B USD
- Year-over-year change
- -53.1%
- 4-year CAGR
- +342.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.8B | -53.1% |
| FY2024 | 2024-12-31 | 3.84B | +82796.1% |
| FY2023 | 2023-12-31 | 4.63M | -49.4% |
| FY2022 | 2022-12-31 | 9.15M | +94.8% |
| FY2021 | 2021-12-31 | 4.7M | — |
Stock-Based Compensation vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's LTM Mar 2026 stock-based compensation of $1.48M is the 4th largest of the 6 companies compared; the peer median is $237K.
- Its year-over-year change of -62.7% is the 3rd highest of 5, against a peer median of -54.7%.
- Over three fiscal years its annual growth of +481.3% compares with a peer median of +26.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.79B | -27809.6% | +824.6% | — | |
| LTM Dec 2025 | $10.38M | -11.5% | -13.2% | 39.1% | |
| LTM Mar 2026 | $2.91M | +50.5% | +4.3% | — | |
| LTM Mar 2026 | $1.48M | -62.7% | +481.3% | — | |
| LTM Jun 2026 | $237K | -98.0% | +48.7% | 0.7% | |
| LTM Dec 2025 | $0 | — | — | — | |
| Peer median (excluding ANVS) | $237K | -54.7% | +26.5% | 19.9% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.49M) | (25.33M) | (56.2M) | (24.59B) | (28.85B) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.7M | 9.15M | 4.63M | 3.84B | 1.8B |
| Change in Working Capital | 657.35K | (1.14M) | (228.6K) | 681.71K | 1.58M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 346.22K | 3.27M | (2.67M) | 1.01M | 284.54K |
| Other Working Capital | 311.13K | (4.41M) | 2.44M | (331.43K) | 1.29M |
| Other Non-Cash Items | 0 | 0 | 11.84M | (1.14B) | 1.44B |
| Operating Cash Flow | (9.13M) | (17.31M) | (39.97M) | (21.89B) | (25.62B) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 46.65M | 4.61K | 16.89M | 18.67M | 34.6M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 95.1K | 0 | 458.39K | 26.67B | 34.57B |
| Financing Cash Flow | 46.74M | 4.61K | 17.34M | 26.69B | 34.6B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.61M | (17.31M) | (22.62M) | 4.8B | 8.98B |
| Free Cash Flow | (9.13M) | (17.31M) | (39.97M) | (21.89B) | (25.62B) |
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.